Aradigm Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)

Aradigm to Earn $4 Million Milestone Payment Upon Commercial Launch and Royalties on Sales

HAYWARD, Calif., Jul 16, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTC BB: ARDM.OB) ("Aradigm") today announced that Zogenix, Inc. was granted approval of the Sumavel(TM) DosePro(TM) (sumatriptan injection) needle-free delivery system which enables subcutaneous delivery of sumatriptan without a needle for the treatment of acute migraine. Aradigm is entitled to a $4 million milestone payment upon first commercial sale, and royalty payments upon any sales of products in the U.S. and other countries, including the European Union, which may be developed and sold using the DosePro technology.

Sumavel DosePro uses the novel, proprietary DosePro drug delivery system to subcutaneously administer sumatriptan, a medication that has been used to treat migraines effectively and safely for over fifteen years, but without many of the issues associated with needle delivery. Sumavel DosePro has the potential of offering migraine relief beginning in as little as ten minutes, in a system sufferers can self administer in three easy steps. Given the unique attributes of Sumavel DosePro, Zogenix believes it has the potential to be used as a replacement for needle-based injectable forms of sumatriptan, as well as to replace tablet and nasal spray triptans for challenging migraine episodes. Migraine affects approximately 30 million people in the United States. Patients suffer with extreme pain, nausea, vomiting, and sensitivity to light and sound, making it difficult to undertake work or other activities. Because of this, speed of relief is a key attribute identified by migraine patients when choosing a medication.

In August 2006, Aradigm sold all of its assets related to the Intraject(TM) needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a private company. Zogenix is responsible for development and commercialization efforts of Intraject (now rebranded under the name DosePro).

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including payments of milestones and royalties, plans for commercialization of DosePro products and the potential for sales of DosePro products, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the Company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Other names and brands may be claimed as the property of others.

SOURCE: Aradigm Corporation

Aradigm
Investor Relations, 510-265-8850/9370
or
Investors
Lippert/Heilshorn & Associates
Don Markley/Bruce Voss, 310-691-7100
dmarkley@lhai.com

Copyright Business Wire 2009

Close window | Back to top